In NAFLD, EGR1 inhibits the transcription of fatty acid oxidation genes in a peroxisome proliferator-activated receptor alpha (PPARα)-dependent manner, thereby affecting lipid metabolism. The gene discussed is EGR1; the disease is metabolic dysfunction-associated steatotic liver disease.